UTHR Earnings & Financial Statements
United Therapeutics Corporation
$540.03
-$3.37(-0.62%)
74
Overall
80
Value
75
Tech
68
Quality
Market Cap
$23.16B
Volume
844.17K
52W Range
$409.07 - $609.35
Target Price
$645.50
UTHR earnings and financial statements: United Therapeutics Corporation's income statement, balance sheet and cash flow statement, annual and quarterly.
UTHR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B |
| Cost of revenue | $384.40M | $309.70M | $257.50M | $151.60M | $122.50M |
| Operating income | $1.49B | $1.38B | $1.18B | $979.70M | $555.90M |
| EBITDA | $1.82B | $1.65B | $1.39B | $1.03B | $662.40M |
| Net income | $1.33B | $1.20B | $984.80M | $727.30M | $475.80M |
| EPS (diluted) | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $7.88B | $7.36B | $7.17B | $6.04B | $5.17B |
| Total liabilities | $783.80M | $920.00M | $1.18B | $1.25B | $1.21B |
| Shareholders’ equity | $7.10B | $6.44B | $5.98B | $4.80B | $3.96B |
| Cash and equivalents | $1.56B | $1.70B | $1.21B | $961.20M | $894.80M |
| Long-term debt | - | - | $300.00M | $800.00M | $800.00M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $1.56B | $1.33B | $978.00M | $802.50M | $598.20M |
| Capital expenditure | -$526.00M | -$246.50M | -$230.40M | -$138.80M | -$120.80M |
| Free cash flow | $1.04B | $1.08B | $747.60M | $663.70M | $477.40M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | UTHR | $540.03 | -0.6% | 844.17K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get United Therapeutics Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW